Brief: Hyloris Renegotiates License Agreements With Alter Pharma Group

Hyloris Pharmaceuticals SA

24/06/2021 06:10

June 24 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * REG-HYLORIS SUCCESSFULLY RENEGOTIATES LICENSE AGREEMENTS
FOR
LEAD PRODUCTS WITH THE ALTER PHARMA GROUP
    * GAINS HIGHER NET PROFIT MARGIN FOR FUSIDIC ACID CREAM IN
CANADA
    * ASSUMES SOLE RESPONSIBILITY FOR HY-075 AND HY-038 - FUTURE
PROFIT SPLIT LAPSES
    * ACQUIRES ALL ROYALTY RIGHTS TO MAXIGESIC IV
    * HAS SUCCESSFULLY RENEGOTIATED AND UNWOUND ITS EARLIER
LICENSE
AGREEMENTS WITH ALTER PHARMA GROUP
    * HYLORIS WILL PAY ALTER PHARMA GROUP A TOTAL LUMP SUM OF
EUR 5.25
MILLION PLUS EUR 0.5 MILLION POTENTIAL EARN-OUT, THEREBY WAIVING
ANY FURTHER FUTURE FINANCIAL OBLIGATIONS TOWARDS ALTER PHARMA
GROUP

Source text for Eikon:  ID:nGNE6pLWwv 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))